Therapeutic antibodies have become a promising way to fight infectious diseases. We are a leading company in this field and have been at the forefront of developing innovative therapeutic antibody solutions. From antibody preparation, screening, optimization, characterization to preclinical research, we provide one-stop services for antibody development to accelerate the R&D process of infectious disease antibody drugs.
Overview of Therapeutic Antibodies
Ever since the historic approval of the inaugural therapeutic monoclonal antibody (mAb) back in the distant year of 1986, the realm of therapeutic antibody drugs has embarked on an exhilarating journey of rapid development. Due to high specificity and low adverse reactions of mAbs, antibody drugs have been widely used in the treatment of infectious diseases. By binding to specific targets, therapeutic antibodies can regulate biological processes, neutralize harmful pathogens, or enhance immune responses, making them valuable tools in combating infectious diseases.
Fig. 1 Engineering therapeutic antibodies to combat infectious diseases. (Wagner E K, Maynard J A., 2018)
Market Size of Therapeutic Antibodies
The market for therapeutic antibodies has experienced remarkable growth in recent years, driven by the increasing demand for effective treatments against infectious diseases. Research reports indicate that the global monoclonal antibody therapeutics market size is estimated at USD 252.6 billion in 2024 and is expected to reach USD 497.5 billion by 2029, with a CAGR of 14.5% from 2024 to 2029. Infectious disease applications play a significant role in this growth.
Fig. 2 Number of therapeutic antibodies against different targets and mAb targets currently in Phase 3 clinical trials. (Martineau P, et al., 2019)
Therapeutic Antibodies for Infectious Diseases
With the advancement of antibody preparation and screening technologies, a variety of antibodies have been approved for the treatment of infectious diseases.
| Therapeutic Antibodies |
Targets |
Mechanism |
Indications |
| Palivizumab |
Respiratory syncytial virus (RSV) fusion (F) protein |
Prevent the fusion of the virus with the host cell |
Respiratory syncytial virus (RSV) infection |
| Raxibacumab |
Bacillus anthracis protective antigen |
Block the binding of other components of the toxin to inhibit the toxin's harmful effects |
Anthrax infection |
| Bezlotoxumab |
Clostridium difficile toxin B |
Neutralize toxic effects of toxin B |
Clostridium difficile infection |
| Oritavancin |
Bacterial Cell Wall Precursor Lipid II |
Disrupt cell wall synthesis |
Skin infections caused by susceptible gram-positive bacteria |
Our Services
Therapeutic antibodies have revolutionized the field of infectious disease treatment, providing targeted and effective solutions for a variety of pathogens. With advanced technology platforms, our company provides one-stop solutions for antibody preparation, screening, optimization and characterization. We are committed to developing comprehensive, high-quality, customizable therapeutic antibodies to promote precise treatment and effective management of infectious diseases.
Antibody Preparation and Screening Platforms
- Hybridoma Technology
- Single B Cell Technology
- Phage display technology
- Yeast display technology
- Bacterial display technology
- Mammalian cell display technology
- Ribosome and mRNA display technology
- And More
Antibody Optimization and Characterization Platforms
- Antibody humanization
- Antibody affinity maturation
- Antibody fragmentation
- KD measurement
- Epitope mapping
- Purity and stability analysis
- Glycosylation analysis
- And More
Development Process of Therapeutic Antibodies
Antibody Characterization
Optional Antibody Types
- Monoclonal antibody (mAb)
- Polyclonal antibody (pAb)
- Bispecific antibody (BsAb)
- Antibody-drug conjugate (ADC)
- Single domain antibody (sdAb)
- And More
Applicable Disease Types
Our company is committed to continuously pushing the boundaries of therapeutic antibody development. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Wagner E K, Maynard J A. Engineering therapeutic antibodies to combat infectious diseases[J]. Current opinion in chemical engineering, 2018, 19: 131-141.
- Martineau P, Watier H, Pèlegrin A, et al. Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France[C]//MAbs. Taylor & Francis, 2019, 11(5): 812-825.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
